IMPLANET Signs an Agreement With Sanyou Medical for a Proposed Capital Increase With Preferential Subscription Rights

2 years ago

Proposed capital increase with preferential subscription rights, to be carried out in January 2024 to strengthen IMPLANET’s equity capital and…

FendX Technologies Inc. to Present at the Emerging Growth Conference on October 4, 2023

2 years ago

FendX Technologies Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation…

IMPLANET Publishes Its 2023 Half-Year Results

2 years ago

Revenue of €4.3 million in the first half of 2023, +4% compared with H1 2022 Continued dynamic R&D investment coupled…

Genflow Biosciences PLC Announces Half-year Report

2 years ago

LONDON, UK / ACCESSWIRE / September 28, 2023 / Genflow (LSE:GENF) is pleased to announce its half year results for…

Update on MedMira’s Regulatory Path in Canada and the USA

2 years ago

HALIFAX, NS / ACCESSWIRE / September 27, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) provides an update on its progress…

Hemostemix Announces Private Placement

2 years ago

Calgary, Alberta--(Newsfile Corp. - September 27, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce…

Addiction Helpline America: Expanding Support for Individuals with Substance Use Disorders

2 years ago

SEBASTIAN, FL / ACCESSWIRE / September 27, 2023 / Addiction Helpline America, a no-cost to consumer drug and alcohol treatment…

Where Aesthetics Meet Empowerment and Safety: Hadeed Plastic Surgery Redefines Personalized Care

2 years ago

BEVERLY HILLS, CA / ACCESSWIRE / September 26, 2023 / In a world where the intersection of aesthetics and empowerment…

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

2 years ago

Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 millionRecord Q4 2023 total prescriptions increased 32% compared to…

MMRF Research Programs Expand Understanding of the Biology of Multiple Myeloma and Patient-Reported Outcomes in New Data Featured at the 20th IMS Annual Meeting

2 years ago

Findings underscore the ongoing value to the myeloma scientific community of the MMRF’s landmark molecular and clinical data and translational…